Over jou

Dianabol Cycle Pharma TRT

**Potential Side‑Effect Profile of Steroids (Glucocorticoids & Androgenic Steroids)**

| Category | Commonly Reported Adverse Effects | Key Risk Factors | Practical Mitigation Strategies |
|----------|----------------------------------|------------------|---------------------------------|
| **Metabolic** | Hyperglycaemia, weight gain, dyslipidaemia (↑ LDL/↓ HDL) | Diabetes mellitus, obesity, pre‑diabetes | • Baseline HbA1c & lipid panel
• Tight glycaemic control; consider dose‑reduction or alternate agents if hyperglycaemia occurs |
| **Endocrine** | Hypothalamic‑pituitary‑adrenal (HPA) axis suppression, osteoporosis, amenorrhoea/menstrual irregularities | Long‑term use (>3 months), high doses >20 mg/day prednisone equivalent | • Periodic bone density scans; calcium/vitamin D supplementation
• Monitor adrenal function if tapering or abrupt cessation |
| **Immunologic** | Increased infection risk (bacterial, viral) | Patients with chronic immunosuppression or comorbidities | • Vaccination status review; prophylactic measures; early evaluation of febrile illnesses |
| **Metabolic** | Hyperglycaemia, weight gain, hypertension, dyslipidaemia | Diabetes mellitus or metabolic syndrome | • Routine fasting glucose/ HbA1c monitoring
• Blood pressure and lipid profile checks |
| **Psychiatric** | Mood swings, anxiety, insomnia, psychosis | Pre‑existing psychiatric disorders | • Psychiatric screening at baseline; ongoing assessment |

---

## 2. Clinical Monitoring & Follow‑Up Plan

| Time after initiation | Assessment | Frequency | Target/Thresholds |
|-----------------------|------------|-----------|-------------------|
| **Baseline (Day 0)** | Full medical history, physical exam, vitals, weight, BMI, CBC, CMP, fasting glucose/HbA1c, lipid panel, BP. Baseline mood and sleep questionnaires. | 1 visit | Baseline values |
| **Week 2** | Vitals, weight, review of side effects (nausea, abdominal pain, constipation), medication adherence, mood/sleep survey. | 1 visit | Detect early GI or psychiatric symptoms; adjust dose if needed |
| **Month 1** | Repeat vitals, weight, BP, fasting glucose/HbA1c, lipid panel, CBC, CMP, review of side effects, dose titration to therapeutic range (if not already). | 1 visit | Adjust dose based on tolerability and efficacy; monitor labs |
| **Months 3–12** | Every 2–3 months: vitals, weight, BP, fasting glucose/HbA1c, lipid panel. Labs (CBC, CMP) every 6 months. Review side effects, adherence. | 1 visit each interval | Early detection of metabolic changes; catch emergent side effects |
| **Adverse Event Monitoring** | Patients instructed to report new symptoms: fatigue, dizziness, nausea, vomiting, weight loss/gain, sexual dysfunction, visual changes. | As needed | Prompt assessment and management (dose adjustment, discontinuation) |

#### 4.3 Early Detection of Metabolic Changes

- **Weight Gain / BMI Increase**: Monitor at each visit; if ≥5% increase in body weight or BMI >30 kg/m², evaluate for lifestyle counseling.
- **Blood Pressure Rise**: If systolic BP increases by ≥10 mmHg or diastolic by ≥6 mmHg from baseline, consider antihypertensive therapy initiation or adjustment.
- **Fasting Glucose/HbA1c Elevation**: Any rise in fasting glucose >5.5 mmol/L (100 mg/dL) warrants further testing and possible referral to endocrinology.

Early interventi

Profielinformatie